Education
About Us
Working with TipRanks
Follow Us
ENDRA Life Sciences Inc (NDRA)
NASDAQ:NDRA
Top Page
ENDRA Life Sciences
(NASDAQ:NDRA)
Select Model
Select Model
Rating:42Neutral
Price Target:
$4.50
▼(-4.05% Downside)
NDRA scores low primarily due to very weak financial performance (no reported revenue, persistent losses, significant cash burn, and reduced equity cushion). Technical indicators are also bearish with the price below key moving averages and a negative MACD, partially offset by near-oversold stochastic conditions. Valuation provides limited support because negative earnings make the P/E not meaningful and no dividend yield is provided.
Positive Factors
Innovative Product
The TAEUS system offers a non-invasive, cost-effective solution for liver disease diagnostics, positioning ENDRA as a potential leader in medical diagnostics innovation.
Strategic Partnerships
Strategic partnerships can enhance market penetration and technology adoption, potentially driving long-term revenue growth and operational success.
Manageable Leverage
A low debt-to-equity ratio suggests financial prudence, providing ENDRA with flexibility to invest in growth opportunities without excessive financial strain.
Negative Factors
Lack of Revenue
Persistent lack of revenue generation indicates challenges in market traction and product monetization, threatening long-term financial viability.
Negative Cash Flow
Negative cash flow from operations suggests difficulties in sustaining operations without external financing, impacting long-term sustainability.
Shrinking Equity
Deteriorating equity and ongoing losses undermine financial health, limiting the company's ability to invest in growth and innovation.
ENDRA Life Sciences (NDRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.35M
Dividend YieldN/A
Average Volume (3M)514.97K
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue GrowthN/A
EPS Growth98.86%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-2.10
Shares Outstanding1,166,441
10 Day Avg. Volume1,472,495
30 Day Avg. Volume514,968
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.74
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market Cap0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.71
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$30.00Price Target Upside539.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ENDRA Life Sciences Business Overview & Revenue Model
Company DescriptionENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
How the Company Makes MoneyENDRA Life Sciences generates revenue primarily through the sale and licensing of its TAEUS system. As the company targets healthcare providers, hospitals, and clinics, its revenue model relies on the adoption of its technology within the medical community. ENDRA may also engage in strategic partnerships or collaborations with other medical technology companies or research institutions to expand the application and reach of its technology. Additionally, the company might explore opportunities to generate revenue through service agreements or support contracts related to its TAEUS system. However, detailed financial data or specific partnership information is not available.
ENDRA Life Sciences Earnings Call Summary
Earnings Call Date:Aug 22, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Mar 26, 2026
Earnings Call Sentiment Neutral
The earnings call presented several strategic initiatives aimed at improving ENDRA's focus and operational efficiency, alongside positive developments in management, regulatory strategy, and intellectual property. However, financial challenges and stock performance issues remain concerns.Q2-2024 Updates
Positive Updates
Enhanced Management Team
ENDRA has strengthened its management team by adding two experienced operators: Richard Jacroux as CFO and Ziad Rouag as Head of Clinical and Regulatory Affairs, both bringing significant expertise in transforming technology companies and navigating regulatory processes.
Strategic Regulatory Changes
The company is implementing a new FDA regulatory strategy, transitioning from retrospective data to a hypothesis-driven, statistically-powered prospective clinical trial, increasing the number of subjects from 20 to about 250 to achieve statistical power.
Significant Reduction in Operating Expenses
ENDRA reduced operating expenses by over $3 million, approximately a 26% reduction on an annualized basis, without impacting key deliverables, such as clinical data collection for FDA submission.
Strong Intellectual Property Portfolio
The patent portfolio now includes 81 issued patents globally, with 5 additional patents issued in Q2 2024, covering thermoacoustic technology and other applications.
Positive FDA Alignment
Positive feedback from an FDA meeting confirmed alignment on product configuration, clinical study design, and regulatory pathway, setting a clear path for the TAEUS liver device.
Negative Updates
Reverse Stock Split Challenges
The reverse stock split intended to maintain NASDAQ listing was derailed by high volume of exercised warrants, resulting in trading below $1, creating uncertainty for the company's stock performance.
Limited Cash Runway
As of June 30, 2024, ENDRA had cash and cash equivalents of $6.4 million, projected to fund operations only into the first half of 2025, highlighting potential future financial constraints.
Company Guidance
During the ENDRA Life Sciences Q2 2024 earnings call, significant guidance was provided by the management team, outlining various strategic initiatives. Notably, the company has completed a 1-for-50 reverse stock split aimed at maintaining its NASDAQ listing, though recent high warrant exercise volumes have impacted their stock price adversely. Six key operational changes were introduced, including the enhancement of the management team with the addition of a seasoned CFO and a new Head of Clinical and Regulatory Affairs. The company plans to conduct a statistically-powered multicenter prospective clinical trial, expanding the number of subjects from 20 to 250. The financial update revealed a $7.3 million net raise from a public offering, with operating expenses reduced by 26% on an annual basis. ENDRA's goal is to complete clinical work and submit a de novo application to the FDA by mid-2025, with the current cash runway projected to fund the company into the first half of 2025. The management reiterated their confidence in ENDRA's technology and market potential, highlighting ongoing efforts to formalize a long-term business strategy and improve financial execution.ENDRA Life Sciences Financial Statement Overview
Summary
ENDRA Life Sciences faces significant financial challenges, as evidenced by its lack of revenue generation and ongoing losses. While the company has managed to maintain liquidity through financing, its long-term sustainability hinges on achieving revenue growth and improving operational efficiencies.Income Statement
The company has consistently reported zero revenue, resulting in an inability to calculate profit margins. The net losses have persisted over the years, showing no signs of revenue generation or operational profitability. This reflects significant challenges in achieving market traction or product monetization.6
Very Negative
Balance Sheet
The debt-to-equity ratio is relatively low, indicating manageable leverage. However, the shrinking stockholders' equity and continuous losses have weakened the balance sheet over time. The company has managed to maintain cash reserves through financing activities, but overall financial stability remains a concern.18
Very Negative
Cash Flow
The company experiences negative operating cash flow, indicating a lack of operational cash generation. Although financing activities have provided necessary liquidity, the consistent negative free cash flow highlights a challenging cash management situation.10
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -164.13K | 0.00 | -275.45K | -234.26K | -224.41K | -165.25K |
| EBITDA | -7.84M | -10.77M | -9.78M | -12.94M | -11.01M | -11.33M |
| Net Income | -8.01M | -11.51M | -10.06M | -13.18M | -11.23M | -11.73M |
Balance Sheet | ||||||
| Total Assets | 1.96M | 4.45M | 6.75M | 9.27M | 12.87M | 8.76M |
| Cash, Cash Equivalents and Short-Term Investments | 794.04K | 3.23M | 2.83M | 4.89M | 9.46M | 7.23M |
| Total Debt | 525.33K | 584.42K | 394.40K | 546.63K | 796.09K | 769.34K |
| Total Liabilities | 1.79M | 1.89M | 1.10M | 2.07M | 2.09M | 1.60M |
| Stockholders Equity | 171.38K | 2.56M | 5.66M | 7.20M | 10.78M | 7.17M |
Cash Flow | ||||||
| Free Cash Flow | -5.10M | -7.42M | -9.58M | -12.97M | -11.17M | -10.82M |
| Operating Cash Flow | -5.09M | -7.40M | -9.55M | -12.77M | -11.12M | -10.77M |
| Investing Cash Flow | -17.28K | -12.80K | -24.72K | -202.58K | -45.00K | -51.33K |
| Financing Cash Flow | 1.15M | 7.81M | 7.52M | 8.40M | 13.40M | 11.88M |
ENDRA Life Sciences Technical Analysis
Negative
4.69
Price Trends
5.34
Negative
5.30
Negative
4.92
Negative
Market Momentum
-0.24
Negative
40.06
Neutral
58.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NDRA, the sentiment is Negative. The current price of 4.69 is below the 20-day moving average (MA) of 4.76, below the 50-day MA of 5.34, and below the 200-day MA of 4.92, indicating a bearish trend. The MACD of -0.24 indicates Negative momentum. The RSI at 40.06 is Neutral, neither overbought nor oversold. The STOCH value of 58.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NDRA.
ENDRA Life Sciences Risk Analysis
ENDRA Life Sciences disclosed 46 risk factors in its most recent earnings report. ENDRA Life Sciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ENDRA Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $14.97M | -0.84 | -223.45% | ― | 3.26% | 65.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $10.15M | ― | ― | ― | ― | ― | |
42 Neutral | $5.35M | -0.33 | -236.34% | ― | ― | 98.86% | |
42 Neutral | $7.07M | >-0.01 | -259.18% | ― | -21.79% | 86.75% | |
42 Neutral | $3.31M | -0.05 | -296.20% | ― | -67.73% | 58.35% |
* Healthcare Sector Average
NDRA
ENDRA Life Sciences
4.47
-1.46
-24.62%
BNBX
BNB Plus
1.63
-140.87
-98.86%
INBS
Intelligent Bio Solutions
14.42
1.32
10.08%
ISPC
iSpecimen
0.42
-2.43
-85.26%
BGLC
BioNexus Gene Lab Corp
3.69
-0.11
-2.89%
MYNZ
Mainz Biomed B.V.
1.19
-3.46
-74.41%
ENDRA Life Sciences Corporate Events
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
ENDRA Life Sciences Granted Nasdaq Compliance Extension
Neutral
Nov 14, 2025
On October 31, 2025, ENDRA Life Sciences received an extension from Nasdaq to November 24, 2025, to regain compliance with the $2.5 million stockholders’ equity requirement. The company had previously submitted a compliance plan and engaged in financial activities, including a private placement offering and a digital asset purchase, to address the shortfall. As of the latest report, ENDRA believes it has met the equity requirement, but Nasdaq will continue to monitor its compliance, with potential delisting if future reports do not show sustained compliance.
The most recent analyst rating on (NDRA) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on ENDRA Life Sciences stock, see the NDRA Stock Forecast page.
Business Operations and StrategyPrivate Placements and Financing
ENDRA Life Sciences Signs Sales Agreement with Lucid
Neutral
Oct 30, 2025
On October 29, 2025, ENDRA Life Sciences Inc. entered into an At-The-Market Issuance Sales Agreement with Lucid Capital Markets, allowing the company to sell shares of its common stock for up to $1,750,000. This agreement provides ENDRA with flexibility in raising capital through equity offerings, potentially impacting its financial strategy and market presence.
The most recent analyst rating on (NDRA) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on ENDRA Life Sciences stock, see the NDRA Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.